Cysteine
Active ingredient: Cysteine Hydrochloride
In short: Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition.
What is Cysteine used for?
Cysteine hydrochloride injection, USP is indicated for use as an additive to amino acids solutions to meet nutritional requirements of neonates (preterm and term infants less than one month of age) requiring total parenteral nutrition.
Cysteine dosage
Cysteine hydrochloride injection, USP is for intravenous infusion after dilution and admixing use only. Prior to administration, cysteine hydrochloride injection, USP must be diluted and used as an admixture in parenteral nutrition solutions.
The resulting solution is for intravenous infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter .
•Prior to administration, cysteine hydrochloride injection, USP must be diluted and used as an admixture in parenteral nutrition solutions.
•Cysteine hydrochloride injection, USP is to be prepared only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.
•Cysteine hydrochloride injection, USP is for addition to amino acid solutions prior to further admixing with dextrose injection using a parenteral nutrition container.
•Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates .
•Use a dedicated line for parenteral nutrition solutions.
•Intravenous lipid emulsions can be infused concurrently into the same vein as cysteine hydrochloride injection, USP-containing amino acid and dextrose solutions by a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps.
•For administration, use a 0.22 micron in-line filter.
•To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
•Visually inspect the diluted parenteral nutrition solution containing cysteine hydrochloride injection, USP for particulate matter and discoloration before admixing, after admixing, after removal from refrigeration, and prior to administration. The solution should be clear and there should be no precipitates. A slight yellow color does not alter the quality and efficacy of this product.
•Remove cysteine hydrochloride injection, USP vial from the carton and inspect for particulate matter. …
How to take Cysteine — instructions & advice from the label
Inform caregivers or home healthcare providers of the following risks of cysteine hydrochloride injection, USP:
•Pulmonary embolism due to pulmonary vascular precipitates
•Vein damage and thrombosis
•Increased BUN
•Acid-base imbalance
•Hepatobiliary disorders
•Aluminum toxicity
•Monitoring and laboratory tests
Manufactured for:
Baxter Healthcare Corporation,
Deerfield, IL 60015, USA
Baxter is a registered trademark of Baxter International Inc.
Rev. 04/22
07-19-00-4043
Warnings & precautions
Do not take this medicine if: Cysteine hydrochloride injection, USP is contraindicated in:
•Patients with known hypersensitivity to one or more amino acids.
•Patients with inborn errors of amino acid metabolism due to risk of severe metabolic or neurologic complications.
•Patients with pulmonary edema or acidosis due to low cardiac output.
Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some fatal cases, pulmonary embolism occurred as a result of calcium phosphate precipitates. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the parenteral nutrition infusion and initiate a medical evaluation. In addition to inspection of the solution , the infusion set and catheter should also periodically be checked for precipitates.
Cysteine hydrochloride injection, USP must be diluted and used as an admixture in parenteral nutrition solutions. Solutions with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter . The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.
Intravenous infusion of amino acids may induce a rise in blood urea nitrogen (BUN), especially in patients with impaired hepatic or renal function. Appropriate laboratory tests should be performed periodically and infusion discontinued if BUN levels exceed normal postprandial limits and continue to rise. …
Cysteine side effects
The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information:
•Pulmonary embolism due to pulmonary vascular precipitates
•Vein damage and thrombosis
•Increased BUN
•Acid-base imbalance
•Hepatobiliary disorders
•Aluminum toxicity
Adverse reactions with the use of cysteine hydrochloride injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
•Metabolic acidosis
•Local infusion site reactions, including a warm sensation, erythema, phlebitis, and thrombosis at the infusion site
•Generalized flushing, fever, and nausea
About this medicine
Cysteine hydrochloride injection, USP (cysteine hydrochloride injection) is a sterile, nonpyrogenic solution for intravenous use supplied as 500 mg/10 mL cysteine hydrochloride, USP in a single-dose vial.
Each mL of cysteine hydrochloride injection, USP contains 50 mg of cysteine hydrochloride, (equivalent to 34.5 mg of cysteine), and 0.006 mL of hydrochloric acid (6M) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH. The pH range of cysteine hydrochloride injection, USP is 1.0 to 1.5.
The active ingredient is cysteine hydrochloride. The chemical name of cysteine hydrochloride is L-cysteine hydrochloride monohydrate. Its molecular formula is C3H7NO2S • HCI • H2O and molecular weight is 175.63. The chemical structure of L-cysteine hydrochloride monohydrate is depicted below:
Cysteine hydrochloride is a white crystalline powder soluble in water. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cbf70fc3-14b3-4c17-8de8-acba1e12ac95. Read the full official label on DailyMed.